SARS-CoV-2 pandemic has contributed to implement telemedicine, allowing clinicians to follow the patient remotely, therefore minimizing the risk of any exposure to positive COVID-19 patients. We summarize the approaches adopted to treat and monitor severe asthmatic patients during the lockdown phase of the pandemic. Our experience supports the strategy that every effort should be made to minimize patient contact with the health-care system, planning a pathway that allows patients to receive appropriate medical care and continue the biological therapies, thus preventing the loss of disease control and acute severe exacerbations.

Benfante A., Principe S., Cicero M.N., Incandela M., Seminara G., Durante C., et al. (2022). Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2021.102083].

Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave

Benfante A.
;
Principe S.;Cicero M. N.;Incandela M.;Seminara G.;Durante C.;Scichilone N.
2022-01-01

Abstract

SARS-CoV-2 pandemic has contributed to implement telemedicine, allowing clinicians to follow the patient remotely, therefore minimizing the risk of any exposure to positive COVID-19 patients. We summarize the approaches adopted to treat and monitor severe asthmatic patients during the lockdown phase of the pandemic. Our experience supports the strategy that every effort should be made to minimize patient contact with the health-care system, planning a pathway that allows patients to receive appropriate medical care and continue the biological therapies, thus preventing the loss of disease control and acute severe exacerbations.
2022
Settore MED/10 - Malattie Dell'Apparato Respiratorio
Benfante A., Principe S., Cicero M.N., Incandela M., Seminara G., Durante C., et al. (2022). Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2021.102083].
File in questo prodotto:
File Dimensione Formato  
Benfante_PPT_21.pdf

accesso aperto

Descrizione: Articolo completo
Tipologia: Versione Editoriale
Dimensione 708.9 kB
Formato Adobe PDF
708.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/547973
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact